Physician profile
Brigetta D Yancy
NPI 1063475499
$16,454.71
in general payments reported to CMS, 2019-2025
45 companies · $2,827 in 2025
The $2,827 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $1,843 · 2021: $2,668 · 2022: $2,581 · 2023: $2,672 · 2024: $2,905 · 2025: $2,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,403.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,388.72 | 2020-2025 | Ubrelvy, Linzess, Vraylar |
| Glaxosmithkline, LLC. | $2,017.69 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,467.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,367.44 | 2019-2025 | |
| Novo Nordisk INC | $1,167.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,014.91 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Scilex Pharmaceuticals INC. | $736.92 | 2021-2025 | Ztlido |
| Bayer Healthcare Pharmaceuticals INC. | $722.90 | 2021-2025 | |
| Astellas Pharma US INC | $520.06 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $511.30 | 2019-2020 | |
| Dexcom, INC. | $500.07 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $479.68 | 2019-2025 | Jardiance |
| Ardelyx, INC. | $385.56 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $361.17 | 2019-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $335.59 | 2019-2024 | Xifaxan, Trulance |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brigetta Yancy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.